Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Irbinitinib
2. N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine
3. N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-4,6-quinazolinediamine
4. Ont-380
5. Tukysa
1. Irbinitinib
2. 937263-43-9
3. Ont-380
4. Tukysa
5. 6-diamine
6. N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine
7. 234248d0hh
8. Irbinitinib; Arry-380; Ont-380
9. 4,6-quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-
10. N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
11. N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-n4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine
12. Tucatinib [inn]
13. 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
14. Unii-234248d0hh
15. Ont 380
16. Tukysa (tn)
17. Ont-380;tucatinib
18. Tucatinib [mi]
19. Tucatinib (usan/inn)
20. Tucatinib [usan:inn]
21. Tucatinib [usan]
22. Irbinitinib(arry-380)
23. Irbinitinib; Arry-380
24. Tucatinib [who-dd]
25. Gtpl9922
26. Schembl1193050
27. Tucatinib [orange Book]
28. Chembl3989868
29. Bdbm471617
30. Dtxsid601027958
31. Bcp15983
32. Ex-a1031
33. Mfcd22380467
34. Nsc764581
35. Nsc799335
36. S8362
37. Zinc68250462
38. Arry-380 (ont-380)
39. Akos026750449
40. Ccg-264747
41. Cs-3906
42. Db11652
43. Nsc-764581
44. Nsc-799335
45. Sb17126
46. Us10822334, Compound Ont380
47. Ncgc00482879-02
48. Ac-33037
49. As-56109
50. Bt177688
51. Hy-16069
52. Example 11 [wo2007059257a2]
53. Db-130430
54. A16413
55. D11141
56. A857335
57. Q25100690
58. 4,6-quinazolinediamine,n6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-n4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-
59. N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-n4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine;
60. N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-n4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-4,6-quinazolinediamine
| Molecular Weight | 480.5 g/mol |
|---|---|
| Molecular Formula | C26H24N8O2 |
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 480.20222204 g/mol |
| Monoisotopic Mass | 480.20222204 g/mol |
| Topological Polar Surface Area | 111 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 796 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Tucatinib is indicated with trastuzumab and capecitabine for treatment of adults diagnosed with advanced unresectable or metastatic HER2-positive breast cancer. This includes patients with brain metastases and those who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2positive locally advanced or metastatic breast cancer who have received at least 2 prior antiHER2 treatment regimens.
By inhibiting tyrosine kinase, tucatinib exerts anti-tumor activity, reducing the size of HER-2 positive breast cancer tumors. In clinical trials, the regimen of tucatinib and [trastuzumab] showed enhanced activity both in vitro and in vivo when compared to either drug administered by itself.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EH - Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitors
L01EH03 - Tucatinib
Absorption
The Tmax for tucatinib ranges from 1 to 4 hours. One pharmacokinetic study revealed a Cmax of 1120 ng/mL after a dose of 350 mg twice daily with a Tmax ranging from 1 to 3 hours. The AUCtau was reported to be about 7120 hoursng/mL.
Route of Elimination
In a study of radiolabled tucatinib, about 86% of the total dose was excreted in the feces and 4.1% was found in the urine. About 16% of the tucatinib dose recovered in the feces was identified as unchanged tucatinib.
Volume of Distribution
The volume of distribution of tucatinib is about 1670 L. This drug penetrates the blood-brain barrier.
Clearance
The apparent clearance is 148 L/h.
Tucatinib is metabolized by CYP2C8 with some contributions from CYP3A.
A pharmacokinetic study revealed a half-life of approximately 5.38 hours. Prescribing information mentions a geometric mean half-life of about 8.21 hours.
Mutations in the HER-2 gene are observed in some types of breast carcinoma. Tucatinib inhibits the tyrosine kinase enzyme of the HER-2 gene. Mutations of tyrosine kinase in the HER-2 gene lead to cascade effects of increased cell signaling and proliferation, resulting in malignancy. Results of in vitro studies show that tucatinib inhibits the phosphorylation of both HER-2 and HER-3, leading to downstream changes in MAPK and AKT signaling and cell proliferation. Anti-tumor activity occured in the cells that expressed HER-2. In vivo, tucatinib has been shown to inhibit HER-2 expressing tumors, likely by the same mechanism.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41453
Submission : 2025-03-28
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41454
Submission : 2025-03-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-03-13
Pay. Date : 2024-02-13
DMF Number : 39450
Submission : 2024-02-01
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41224
Submission : 2025-03-26
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39057
Submission : 2023-10-26
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2024-07-01
Valid Till : 2027-06-30
Written Confirmation Number : WC-0586
Address of the Firm : Unit-III, Sy. No. 111/E & 111/EE, Cheriyal (Village),Kandi (Mandal), Sanga Reddy...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Korea Pfizer Pharmaceutical Co., Ltd.
Registration Date : 2023-12-14
Registration Number : Su90-30-ND
Manufacturer Name : ESTEVE QUIMICA, SA
Manufacturer Address : C/Ter, 94. Polígon Industrial, 17460 Celrà (Girona), Spain

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 57572-0723
Start Marketing Date : 2023-05-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 50909-1911
Start Marketing Date : 2020-04-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (0.5kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 54893-0506
Start Marketing Date : 2024-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65129-1487
Start Marketing Date : 2025-03-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
Lee Fine Chem: Advancing Innovation and Quality in Intermediates, APIs, and Dosage Forms for Superior Pharmaceutical Solutions.
About the Company : Lee Fine Chem Private Limited specializes in advanced intermediates, Active Pharmaceutical Ingredients (APIs), and finished dosage forms. Focused on quality and innovation, we deli...
About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...

About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...

About the Company : Sai Phytoceuticals Pvt. Ltd. Is an ISO 9001:2000 and HACCP certified company established in 2002. The core business of the company focuses on manufacturing and marketing (for domes...

About the Company : Viyash, true to its name, literally represents honesty and leadership in every sense. We are an integrated pharmaceutical company with a strong portfolio of niche formulations, ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Tucatinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Tucatinib,Trastuzumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Pfizer Inc | Eurofins CDMO | UNICANCER
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2025

Lead Product(s) : Tucatinib,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc | Eurofins CDMO | UNICANCER
Deal Size : Inapplicable
Deal Type : Inapplicable
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Details : Tucatinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tukysa (tucatinib) is a HER2 inhibitor, approved in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
Lead Product(s): Tucatinib,Fulvestrant,Trastuzumab
Therapeutic Area: Oncology Brand Name: Tukysa
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tucatinib,Fulvestrant,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer
Details : Tukysa (tucatinib) is a HER2 inhibitor, approved in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
Product Name : Tukysa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tukysa (tucatinib) is a HER2 inhibitor, approved in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
Lead Product(s): Tucatinib,Capecitabine,Trastuzumab
Therapeutic Area: Oncology Brand Name: Tukysa
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tucatinib,Capecitabine,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pfizer Japan Files NDA for Tucatinib for HER2 Breast Cancer
Details : Tukysa (tucatinib) is a HER2 inhibitor, approved in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
Product Name : Tukysa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tuccatinn (tucatinib) is a HER2 inhibitor, approved in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
Lead Product(s): Tucatinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Tuccatinn
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tucatinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
India’s CDSCO Clears BDR Pharma To Make & Market Tucatinib Tablets
Details : Tuccatinn (tucatinib) is a HER2 inhibitor, approved in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
Product Name : Tuccatinn
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2025

Details:
Tucatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Tucatinib,Trastuzumab,Pertuzumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 08, 2023

Lead Product(s) : Tucatinib,Trastuzumab,Pertuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tucatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 08, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Disitamab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Disitamab Vedotin,Tucatinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: RemeGen
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2023

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Details : Disitamab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 06, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Lead Product(s): Tucatinib,Trastuzumab Emtansine
Therapeutic Area: Oncology Brand Name: Tukysa
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tucatinib,Trastuzumab Emtansine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improve...
Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Product Name : Tukysa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2023

Details:
Tucatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Tucatinib,Trastuzumab,Capecitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Pfizer Inc | Biocon Biologics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2023

Lead Product(s) : Tucatinib,Trastuzumab,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc | Biocon Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD
Details : Tucatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Lead Product(s): Tucatinib,Kadcyla
Therapeutic Area: Oncology Brand Name: Tukysa
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2023

Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Product Name : Tukysa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023

Details:
Tucatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Tucatinib,Etoposide,Trastuzumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 21, 2023

Lead Product(s) : Tucatinib,Etoposide,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tucatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 21, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results][1,2,4]Triazolo[1,5-a]pyridin-7-ol
CAS Number : 1033810-70-6
End Use API : Tucatinib
About The Company : Aarti Pharmalabs is generic APIs & Intermediates manufacturing company & small molecule drug substance CDMO and the largest Indian manufacturer of Xanthine Deri...
4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methyl...
CAS Number : 937263-71-3
End Use API : Tucatinib
About The Company : Aarti Pharmalabs is generic APIs & Intermediates manufacturing company & small molecule drug substance CDMO and the largest Indian manufacturer of Xanthine Deri...
(E)-N'-(2-CYANO-4-(3-(1-HYDROXY-2-METHYL PROPAN-2-...
CAS Number : 1429755-57-6
End Use API : Tucatinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

3-METHYL-4-([1,2,4] TRIAZOLO[1,5-A] PYRIDIN-7-YL O...
CAS Number : 937263-71-3
End Use API : Tucatinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

DI (IMIDAZOL-1-YL) METHANE THIONE
CAS Number : 6160-65-2
End Use API : Tucatinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

CAS Number : 6943-17-5
End Use API : Tucatinib
About The Company : Anvitha Life Care Private Limited, founded in 2016 by Dr. T. Prakasam and a team of experienced scientists and technocrats with over 80 years of combined expert...

4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methyl...
CAS Number : 937263-71-3
End Use API : Tucatinib
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

(E)-N'-(2-cyano-4-(3-(1-hydroxy-2-methylpropan-2-y...
CAS Number : 1429755-57-6
End Use API : Tucatinib
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

[1,2,4]triazolo[1,5-a]pyridin-7-ol
CAS Number : 1033810-70-6
End Use API : Tucatinib
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

CAS Number : 19798-80-2
End Use API : Tucatinib
About The Company : Saptagir Laboratories Private incorporated in 2016, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) and Intermediates for a wide rang...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
29
PharmaCompass offers a list of Tucatinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tucatinib manufacturer or Tucatinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tucatinib manufacturer or Tucatinib supplier.
PharmaCompass also assists you with knowing the Tucatinib API Price utilized in the formulation of products. Tucatinib API Price is not always fixed or binding as the Tucatinib Price is obtained through a variety of data sources. The Tucatinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tucatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tucatinib, including repackagers and relabelers. The FDA regulates Tucatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tucatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tucatinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tucatinib supplier is an individual or a company that provides Tucatinib active pharmaceutical ingredient (API) or Tucatinib finished formulations upon request. The Tucatinib suppliers may include Tucatinib API manufacturers, exporters, distributors and traders.
click here to find a list of Tucatinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tucatinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Tucatinib active pharmaceutical ingredient (API) in detail. Different forms of Tucatinib DMFs exist exist since differing nations have different regulations, such as Tucatinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tucatinib DMF submitted to regulatory agencies in the US is known as a USDMF. Tucatinib USDMF includes data on Tucatinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tucatinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tucatinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tucatinib Drug Master File in Korea (Tucatinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tucatinib. The MFDS reviews the Tucatinib KDMF as part of the drug registration process and uses the information provided in the Tucatinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tucatinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tucatinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tucatinib suppliers with KDMF on PharmaCompass.
A Tucatinib written confirmation (Tucatinib WC) is an official document issued by a regulatory agency to a Tucatinib manufacturer, verifying that the manufacturing facility of a Tucatinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tucatinib APIs or Tucatinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Tucatinib WC (written confirmation) as part of the regulatory process.
click here to find a list of Tucatinib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tucatinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tucatinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tucatinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tucatinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tucatinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tucatinib suppliers with NDC on PharmaCompass.
Tucatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tucatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tucatinib GMP manufacturer or Tucatinib GMP API supplier for your needs.
A Tucatinib CoA (Certificate of Analysis) is a formal document that attests to Tucatinib's compliance with Tucatinib specifications and serves as a tool for batch-level quality control.
Tucatinib CoA mostly includes findings from lab analyses of a specific batch. For each Tucatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tucatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Tucatinib EP), Tucatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tucatinib USP).